MEDITERRANEE INFECTION

Their core work

IHU Méditerranée Infection is a clinical and research institute in Marseille specializing in infectious diseases, human microbiome science, and microbial genomics. Their core work involves characterizing how the gut and mucosal microbiome influences disease susceptibility and immune responses — particularly in the context of HIV-1 acquisition, inflammation, and chronic conditions such as cancer and diabetes. They bring strong bioinformatics and high-throughput sequencing capabilities to multi-partner research consortia, typically as a specialist contributor rather than a project lead. Beyond Europe, they actively support the development of microbiome research capacity in North Africa, reflecting a dual role as both a scientific producer and an international capacity builder.

What they specialise in

How they've shifted over time

Their earliest H2020 involvement (MISTRAL, 2020) was tightly focused on the microbiome-immunity axis in infectious disease — specifically gut microbiome, HIV-1 infection, inflammation biomarkers, and immunological aging (inflammaging). By 2021, with MICAfrica, the focus broadened substantially: high-throughput sequencing methods came to the fore, and the disease scope expanded from HIV to cancer and diabetes, suggesting a strategic move toward applying microbiome science across chronic and metabolic conditions. The trajectory points from a single-disease infectious disease lens toward a platform microbiome-profiling capability with multi-disease applicability.

They are evolving from HIV-specific microbiome immunology toward a broader multi-disease microbiome platform, with high-throughput sequencing as the enabling technology — making them an increasingly relevant partner for any consortium tackling cancer, metabolic disease, or personalized medicine through microbial data.

How they like to work

IHU Méditerranée Infection does not coordinate H2020 projects — they enter consortia as a participant or third-party expert, suggesting they prefer to contribute defined scientific deliverables rather than manage administrative complexity. With 16 unique partners across 7 countries from just two projects, they engage in medium-to-large consortia and appear comfortable in geographically diverse partnerships. Their third-party role in MISTRAL indicates they can be brought into a consortium specifically for a bounded scientific contribution, which makes them flexible and low-friction to integrate.

Sixteen unique consortium partners across 7 countries from only 2 projects signals dense, multi-partner consortia rather than bilateral collaboration. Their network spans both European research institutions and North African partners, reflecting a deliberate South-Mediterranean geographic orientation that is rare among French research centres.

What sets them apart

IHU Méditerranée Infection sits at an unusual intersection: a clinically embedded research institute that combines high-throughput microbiome sequencing with deep infectious disease expertise — a combination most pure bioinformatics labs or pure clinical centres lack individually. Their active engagement in African research capacity building gives them a South-Mediterranean network and credibility that most Western European institutes do not have, which is a concrete differentiator for consortia targeting global health, Africa-EU partnerships, or Widening Participation calls. For a consortium needing both rigorous microbiome science and an established African partner network, they are a rare single-organisation solution.

Highlights from their portfolio

• MISTRAL
  A long five-year RIA (2020-2025) covering the full complexity of HIV-1 acquisition risk through a microbiome lens, with one of the broadest keyword profiles in the dataset — spanning gut microbiome, inflammaging, vaccination, immunity, systems biology, and bioinformatics simultaneously.
• MICAfrica
  The sole funded project (EUR 169,502 CSA) and the only one where IHU participates formally — a capacity-building initiative building the first North-African Human Microbiome Consortium, combining sequencing technology transfer with scientific network development across the Mediterranean.